US-based pharmaceutical major Gilead Sciences Inc., (NASDAQ: GILD) has released its financial results for the second quarter of 2023, reporting a 5% year-on-year (YOY) increase in global revenues to USD 6.6 billion. Excluding sales of the COVID-19 drug Veklury (remdesivir), revenues were up 11% YOY to USD 6.3 billion.
HIV and Oncology Products Drive Growth
Gilead’s business is primarily driven by its HIV and oncology product portfolios. HIV products accounted for USD 4.6 billion of Q2 sales, marking a 9% YOY growth. Key products in this category include Biktarvy (bictegravir 50mg/emtricitabine 200mg (FTC)/tenofovir alafenamide 25mg (TAF)), with sales up 17% YOY, and Descovy (FTC 200mg/TAF 25mg), which saw a 12% YOY increase in sales.
Liver Disease and Cell Therapy Products Show Strong Performance
Sales of products targeting liver diseases, including chronic hepatitis C virus (HCV), hepatitis B virus (HBV), and hepatitis delta virus (HDV), increased by 4% YOY to USD 711 million. Cell therapy products experienced a 27% YOY growth, reaching USD 469 million. The CD19-targeted chimeric antigen receptor (CAR) T cell therapy Yescarta (axicabtagene ciloleucel), approved for large B-cell lymphoma (LBCL), led the way with sales of USD 380 million, up 29% YOY. Additionally, Tescarta (brexucabtagene autoleucel), approved for acute lymphoblastic leukemia (ALL) and mantle cell lymphoma (MCL), generated USD 88 million in sales, marking a 21% YOY increase.
Trodelvy’s Impressive Sales Growth
Trodelvy (sacituzumab govitecan), a Trop-2-directed antibody and topoisomerase inhibitor drug conjugate (ADC) for HR+/HER2- breast cancer, saw a remarkable 63% increase in sales, reaching USD 260 million.-Fineline Info & Tech
